Form 10-Q RAPT Therapeutics, Inc. For: Sep 30

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. META
2. TSLA
3. IBM
4. TXN
5. SAP
6. MRNA
7. CSX
8. LVS
9. QGEN
10. SPCX

Go back to Form 10-Q RAPT Therapeutics, Inc. For: Sep 30

Leerink Partners Reiterates Market Perform Rating on Rapt Therapeutics (RAPT)

November 12, 2024 4:08 PM EST

Leerink Partners analyst Thomas Smith reiterated a Market Perform rating and $2.00 price target on Rapt Therapeutics (NASDAQ: RAPT).

The analyst comments "Bottom Line: RAPT reported 3Q24 financial results following the company's decision to terminate development of zelnecirnon (RPT193, oral CCR4 antagonist) based on recent FDA feedback suggesting there was no viable path forward for this program (see our note HERE).... More

Stifel Downgrades Rapt Therapeutics (RAPT) to Hold

November 12, 2024 4:04 PM EST

Stifel analyst Alex Thompson downgraded Rapt Therapeutics (NASDAQ: RAPT) from Buy to Hold with a price target of $2.00 (from $7.00).

The analyst comments "We are downgrading RAPT to Hold following the recent Zelnecirnon program termination (LINK). RAPT discontinued the program following FDA feedback suggesting... More